Companies › Insmed
2 active drug programs in 11 registered trials: 5 Phase 3, 3 Phase 2, 3 Phase 1; Other, Cardiovascular, Gastroenterology, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Treprostinil Prostanoid IP receptor agonist | PTGIR | Phase 3 | Pulmonary Arterial Hypertension; Pulmonary Hypertension; Progressive Pulmonary Fibrosis; Hepatic Impairment … | Dec 2026 |
| INS1033 | – | Phase 1 | Healthy Volunteers | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04062565 | Treprostinil | Phase 3 | Pulmonary Arterial Hypertension | Cardiovascular | Dec 2025 |
| NCT05649748 | Treprostinil | Phase 2 | Pulmonary Arterial Hypertension | Cardiovascular | Dec 2026 |
| NCT06969573 | Treprostinil | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | Respiratory | Dec 2026 |
| NCT07643155 | Treprostinil | Phase 1 | Hepatic Impairment | Gastroenterology | Feb 2027 |
| NCT07765706 | INS1033 | Phase 1 | Healthy Volunteers | Other | Mar 2027 |
| NCT07037836 | Treprostinil | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | Respiratory | Jul 2027 |
| NCT04005469 | Treprostinil | Phase 1 | Ischemia Reperfusion Injury | Other | Jun 2028 |
| NCT07481981 | Treprostinil | Phase 3 | Pulmonary Arterial Hypertension | Cardiovascular | Dec 2028 |
| NCT07179380 | Treprostinil | Phase 3 | Pulmonary Hypertension | Cardiovascular | Dec 2028 |
| NCT07805785 | Treprostinil | Phase 3 | Progressive Pulmonary Fibrosis | Respiratory | Aug 2030 |
| NCT07234032 | Treprostinil | Phase 3 | Pulmonary Hypertension | Cardiovascular | Jan 2031 |
Cash and short-term investments of $1.1bn on 2026-09-30; operating cash outflow about $467m a year; runway about 30 months at that burn, to Mar 2029; 5 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Johnson & Johnson (Janssen) Liquidia Technologies United Therapeutics
Liquidia Technologies Eloxx Pharmaceuticals Tenax Therapeutics Kymera Therapeutics Shanghai Synvida Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.